Investments
31Portfolio Exits
11Funds
9Service Providers
1About HealthCare Ventures
HealthCare Ventures is a life science venture capital firm investing in pre-clinical or early clinical stage, project-focused companies with potential to transform patient care. They aim to identify high potential products within academia or pharmaceutical companies, develop them to clinical proof-of-concept within capital efficient, semi-virtual organizations, and generate superior returns through acquisitions by pharmaceutical and biotechnology companies.
HealthCare Ventures Headquarter Location
47 Thorndike St B1
Cambridge, Massachusetts, 02141,
United States
617-252-4343
HealthCare Ventures Web Traffic
HealthCare Ventures Rank
Latest HealthCare Ventures News
Jul 15, 2022
Saturday, 16 Jul 2022 For decades, Indonesia has been the mecca for many Malaysian plantation companies as a reliable source for migrant estate workers.However, this is no longer the case, especially when Indonesia took over the status of the world’s largest producer of palm oil from Malaysia with many Indonesians opted to stay home and work in the oil palm estates there. Planters’ bane IT was a rude awakening for local planters this week, when Indonesia again displayed its inconsistent policy by freezing the recruitment of its workers for Malaysia. Hopes were dashed for the arrival of the first batch of 32,000 Indonesian workforce meant for the sector here. For decades, Indonesia has been the mecca for many Malaysian plantation companies as a reliable source for migrant estate workers. However, this is no longer the case, especially when Indonesia took over the status of the world’s largest producer of palm oil from Malaysia with many Indonesians opted to stay home and work in the oil palm estates there. Ironically, some of the big oil palm plantations in the republic are also owned by several high-profile Malaysian planters. With the Covid-19 pandemic, the shortage situation in the local plantation scene has escalated further to 120,000 workers currently from about 60,000 workers during the pre-pandemic period. Of the 2.06 million legally-registered foreign workers in Malaysia, the labour-intensive plantation sector hired about 268,203 or about 15.9%, alongside with other sectors such as construction, manufacturing, agricultural and domestic maids. With Indonesia’s latest temporary freeze on its workers for Malaysia, the best bet would be for local planters to seek elsewhere, perhaps from India and Pakistan as suggested by the Plantation Industries and Commodities Minister Datuk Zuraida Kamaruddin. Another alternative is to bump up on the mechanisation and automation in the oil palm estates – an idea which often looks good on paper but still has yet to take off on a successful route. Another suggestion is for the government to provide a higher matching grant from the current RM30mil for investment in the mechanisation and automation in the estate operations. This perhaps could further encourage planters to take on the automation programme on a more serious note. Apparently, the freeze of Indonesian workers to Malaysia also coincides with the upcoming palm oil peak production months. The Malaysian Estate Owners Association reveals that any potential delay in harvesting the fresh fruit bunches may result in its members suffering 5% to 10% losses in earnings due to the current severe labour crunch. Healthcare ventures SUCCESSFUL healthcare providers tend to get ascribed with high valuations. Listed medical groups in Malaysia are a good example. are good examples of having price-earning ratios of more than 30 times. Newcomer Cengild Medical Bhd managed to secure an earnings multiple of 27 times when it was floated earlier this year. The reasons why these companies enjoy a high earnings multiple is because of the high entry barrier to the business. Medical equipment costs a lot and there are other high operational costs too. It also requires a fair bit of expertise and medical personnel who are able to win the trust of the customers. This is why healthcare ventures take a while before they start showing profits let alone sustainable profit margins. During the Covid-19 pandemic, a number of listed companies sought to venture into the healthcare business by announcing businesses related to vaccine distribution or even production. None of the companies have managed to eke out solid profits from those ventures. More stable plans have come from companies such as LYC Healthcare Bhd, which first ventured into healthcare back in 2018 by focusing on a niche. It opened its first mother and child centre that year. The company has made other inroads into the healthcare space, which could prove to be profitable in the future. But for now, it is still remains loss making, indicating the long gestation period for these businesses plus the impact that the pandemic has likely had on it. This week, another loss-making company, Omesti Bhd , said it has formed a joint venture to set up and operate diagnostic and screening centres. Omesti has said that it plans to increase its investment in the healthcare services segment. Payback, though, may not be that fast or lucrative. Article type: free
HealthCare Ventures Investments
31 Investments
HealthCare Ventures has made 31 investments. Their latest investment was in MyOme as part of their Series B on June 6, 2022.
HealthCare Ventures Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
6/21/2022 | Series B | MyOme | $23M | Yes | 2 | |
7/13/2020 | Series B - III | Paige | $20M | Yes | 8 | |
9/12/2011 | Series A | Tensha Therapeutics | $15M | Yes | 3 | |
8/2/2011 | Series A | |||||
1/7/2011 | Series A |
Date | 6/21/2022 | 7/13/2020 | 9/12/2011 | 8/2/2011 | 1/7/2011 |
---|---|---|---|---|---|
Round | Series B | Series B - III | Series A | Series A | Series A |
Company | MyOme | Paige | Tensha Therapeutics | ||
Amount | $23M | $20M | $15M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 2 | 8 | 3 |
HealthCare Ventures Portfolio Exits
11 Portfolio Exits
HealthCare Ventures has 11 portfolio exits. Their latest portfolio exit was Tensha Therapeutics on January 11, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/11/2016 | Acquired | 3 | |||
2/7/2008 | Acquired | Undisclosed Investors | |||
9/15/2001 | Acquired | ||||
Date | 1/11/2016 | 2/7/2008 | 9/15/2001 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Undisclosed Investors | ||||
Sources | 3 |
HealthCare Ventures Fund History
9 Fund Histories
HealthCare Ventures has 9 funds, including HealthCare Ventures VIII LP.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
8/18/2005 | HealthCare Ventures VIII LP | Early-Stage Venture Capital | Closed | $379M | 1 |
11/19/2002 | HealthCare Ventures VII LP | ||||
12/21/2000 | HealthCare Ventures VI LP | ||||
12/31/1997 | HealthCare Ventures V LP | ||||
4/30/1993 | HealthCare Ventures III & IV LP |
Closing Date | 8/18/2005 | 11/19/2002 | 12/21/2000 | 12/31/1997 | 4/30/1993 |
---|---|---|---|---|---|
Fund | HealthCare Ventures VIII LP | HealthCare Ventures VII LP | HealthCare Ventures VI LP | HealthCare Ventures V LP | HealthCare Ventures III & IV LP |
Fund Type | Early-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | $379M | ||||
Sources | 1 |
HealthCare Ventures Service Providers
1 Service Provider
HealthCare Ventures has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Counsel |
Service Provider | |
---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type |
Partnership data by VentureSource
HealthCare Ventures Team
7 Team Members
HealthCare Ventures has 7 team members, including current Managing Director, Douglas E. Onsi.
Name | Work History | Title | Status |
---|---|---|---|
Douglas E. Onsi | Managing Director | Current | |
Harold R. Werner | Managing Director | Current | |
Mads Emil Matthiesen | Owner | Current | |
Fiona Marston | Absynth Biologics, H2O Venture Partners, Novacta Biosystems, Metris Therapeutics, and Celltech | Chief Executive Officer | Former |
James Kuo | Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, Myriad Genetics, and Pfizer | Managing Director | Former |
Name | Douglas E. Onsi | Harold R. Werner | Mads Emil Matthiesen | Fiona Marston | James Kuo |
---|---|---|---|---|---|
Work History | Absynth Biologics, H2O Venture Partners, Novacta Biosystems, Metris Therapeutics, and Celltech | Tryp Therapeutics, Synthetic Biologics, BioMicro Systems, Myriad Genetics, and Pfizer | |||
Title | Managing Director | Managing Director | Owner | Chief Executive Officer | Managing Director |
Status | Current | Current | Current | Former | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.